johnson and johnson glp-1 Hear Why J&J MedTech Is Ready to Move Forward with Ottava; A VC Discusses the Impact of drugs Still On A GLP-1: The

W., Schoenherr, J., Gouker, L., & Lund, E

cagrilintide + tirzepatide The cagrilintide dosage with tirzepatide combination targets three pathways (GLP-1, GIP, and amylin) versus four with the retatrutide combination (GLP-1, GIP, glucagon, and amylin)

Zipursky JS et al

The defining feature of Retatrutide is its ability to activate three key metabolic receptors in one molecule

Hunter K, Hlscher C

A recurring theme across non-incretin metabolic peptides is that early development efforts were constrained by pleiotropy, cardiovascular effects, or incomplete receptor characterization rather than by lack of metabolic relevance